Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2019

Open Access 01-12-2019 | Acute Respiratory Distress-Syndrome | Research

Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits

Authors: J. Zebialowicz Ahlström, F. Massaro, P. Mikolka, R. Feinstein, G. Perchiazzi, O. Basabe-Burgos, T. Curstedt, A. Larsson, J. Johansson, A. Rising

Published in: Respiratory Research | Issue 1/2019

Login to get access

Abstract

Aim

In acute respiratory distress syndrome (ARDS) damaged alveolar epithelium, leakage of plasma proteins into the alveolar space and inactivation of pulmonary surfactant lead to respiratory dysfunction. Lung function could potentially be restored with exogenous surfactant therapy, but clinical trials have so far been disappointing. These negative results may be explained by inactivation and/or too low doses of the administered surfactant. Surfactant based on a recombinant surfactant protein C analogue (rSP-C33Leu) is easy to produce and in this study we compared its effects on lung function and inflammation with a commercial surfactant preparation in an adult rabbit model of ARDS.

Methods

ARDS was induced in adult New Zealand rabbits by mild lung-lavages followed by injurious ventilation (VT 20 m/kg body weight) until P/F ratio < 26.7 kPa. The animals were treated with two intratracheal boluses of 2.5 mL/kg of 2% rSP-C33Leu in DPPC/egg PC/POPG, 50:40:10 or poractant alfa (Curosurf®), both surfactants containing 80 mg phospholipids/mL, or air as control. The animals were subsequently ventilated (VT 8–9 m/kg body weight) for an additional 3 h and lung function parameters were recorded. Histological appearance of the lungs, degree of lung oedema and levels of the cytokines TNFα IL-6 and IL-8 in lung homogenates were evaluated.

Results

Both surfactant preparations improved lung function vs. the control group and also reduced inflammation scores, production of pro-inflammatory cytokines, and formation of lung oedema to similar degrees. Poractant alfa improved compliance at 1 h, P/F ratio and PaO2 at 1.5 h compared to rSP-C33Leu surfactant.

Conclusion

This study indicates that treatment of experimental ARDS with synthetic lung surfactant based on rSP-C33Leu improves lung function and attenuates inflammation.
Appendix
Available only for authorised users
Literature
1.
Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.CrossRef
2.
Haitsma JJ, Lachmann RA, Lachmann B. Lung protective ventilation in ARDS: role of mediators, PEEP and surfactant. Monaldi Arch Chest Dis. 2003;59(2):108–18.PubMed
3.
Wong JJ, Jit M, Sultana R, Mok YH, Yeo JG, Koh J, et al. Mortality in pediatric Acute Respiratory Distress Syndrome: a systematic review and meta-analysis. J Intensive Care Med. 2019;34(7):563–71 Epub 2017/05/04.CrossRefPubMed
4.
Orloff KE, Turner DA, Rehder KJ. The current state of pediatric Acute Respiratory Distress Syndrome. Pediatr Allergy Immunol Pulmonol. 2019;32(2):35–44 Epub 2019/06/27.CrossRefPubMedPubMedCentral
5.
Villar J, Sulemanji D, Kacmarek RM. The acute respiratory distress syndrome: incidence and mortality, has it changed? Curr Opin Crit Care. 2014;20(1):3–9.CrossRefPubMed
6.
Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.
7.
Dushianthan A, Cusack R, Goss V, Postle AD, Grocott MP. Clinical review: exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here? Crit Care. 2012;16(6):238.CrossRefPubMedPubMedCentral
8.
Autilio C, Perez-Gil J. Understanding the principle biophysics concepts of pulmonary surfactant in health and disease. Arch Dis Child Fetal Neonatal Ed. 2019;104(4):F443–F51 Epub 2018/12/16.PubMed
9.
10.
Verbrugge SJ, Sorm V, Lachmann B. Mechanisms of acute respiratory distress syndrome: role of surfactant changes and mechanical ventilation. J Physiol Pharmacol. 1997;48(4):537–57.PubMed
11.
Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol. 2009;40(5):519–35.CrossRefPubMed
12.
Pierrakos C, Karanikolas M, Scolletta S, Karamouzos V, Velissaris D. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res. 2012;4(1):7–16.PubMedPubMedCentral
13.
Bos LDJ, Scicluna BP, Ong DSY, Cremer O, van der Poll T, Schultz MJ. Understanding heterogeneity in biologic phenotypes of Acute Respiratory Distress Syndrome by leukocyte expression profiles. Am J Respir Crit Care Med. 2019;200(1):42–50 Epub 2019/01/16.CrossRefPubMed
14.
15.
Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72(10):876–83 Epub 2017/04/30.CrossRefPubMed
16.
De Luca D. Personalising care of acute respiratory distress syndrome according to patients' age. Lancet Respir Med. 2019;7(2):100–1 Epub 2018/10/27.CrossRefPubMed
17.
De Luca D, Harrison DA, Peters MJ. 'Lumping or splitting' in paediatric acute respiratory distress syndrome (PARDS). Intensive Care Med. 2018;44(9):1548–50 Epub 2018/08/26.CrossRefPubMed
18.
Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.CrossRefPubMed
19.
20.
Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis study group. N Engl J Med. 1996;334(22):1417–21.CrossRefPubMed
21.
Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155(4):1309–15.CrossRefPubMed
22.
Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009;180(10):989–94.CrossRefPubMed
23.
Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, et al. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax. 2007;62(7):588–94.CrossRefPubMedPubMedCentral
24.
Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884–92.CrossRefPubMed
25.
Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003;167(11):1562–6.CrossRefPubMed
26.
Spragg RG, Taut FJ, Lewis JF, Schenk P, Ruppert C, Dean N, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med. 2011;183(8):1055–61.CrossRefPubMed
27.
Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA. 1994;272(18):1433–8.CrossRefPubMed
28.
Meng H, Sun Y, Lu J, Fu S, Meng Z, Scott M, et al. Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials. J Cardiothorac Vasc Anesth. 2012;26(5):849–56.CrossRefPubMed
29.
Seehase M, Collins JJ, Kuypers E, Jellema RK, Ophelders DR, Ospina OL, et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. PLoS One. 2012;7(10):e47631.CrossRefPubMedPubMedCentral
30.
Calkovska A, Linderholm B, Haegerstrand-Bjorkman M, Pioselli B, Pelizzi N, Johansson J, et al. Phospholipid composition in synthetic surfactants is important for tidal volumes and alveolar stability in surfactant-treated preterm newborn rabbits. Neonatology. 2016;109(3):177–85 Epub 2016/01/13.CrossRefPubMed
31.
Davis AJ, Jobe AH, Hafner D, Ikegami M. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med. 1998;157(2):553–9.CrossRefPubMed
32.
Hafner D, Germann PG, Hauschke D. Comparison of rSP-C surfactant with natural and synthetic surfactants after late treatment in a rat model of the acute respiratory distress syndrome. Br J Pharmacol. 1998;124(6):1083–90.CrossRefPubMedPubMedCentral
33.
Willander H, Askarieh G, Landreh M, Westermark P, Nordling K, Keranen H, et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc Natl Acad Sci U S A. 2012;109(7):2325–9.CrossRefPubMedPubMedCentral
34.
Hosia W, Johansson J, Griffiths WJ. Hydrogen/deuterium exchange and aggregation of a polyvaline and a polyleucine alpha-helix investigated by matrix-assisted laser desorption ionization mass spectrometry. Mol Cell Proteomics. 2002;1(8):592–7.CrossRefPubMed
35.
Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of amyloid fibril-forming proteins. J Biol Chem. 2001;276(16):12945–50.CrossRefPubMed
36.
Nilsson G, Gustafsson M, Vandenbussche G, Veldhuizen E, Griffiths WJ, Sjovall J, et al. Synthetic peptide-containing surfactants--evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur J Biochem. 1998;255(1):116–24.CrossRefPubMed
37.
Johansson J, Curstedt T. Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases. J Intern Med. 2018;285(2):165–86.CrossRefPubMed
38.
Johansson J, Some M, Linderholm BM, Almlen A, Curstedt T, Robertson B. A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits. J Appl Physiol. 1985;95(5):2055–63.CrossRef
39.
Curstedt T, Calkovska A, Johansson J. New generation synthetic surfactants. Neonatology. 2013;103(4):327–30.CrossRefPubMed
40.
Kronqvist N, Sarr M, Lindqvist A, Nordling K, Otikovs M, Venturi L, et al. Efficient protein production inspired by how spiders make silk. Nat Commun. 2017;8:15504.CrossRefPubMedPubMedCentral
41.
Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50(6):1007–15 Epub 2013/04/06.CrossRefPubMed
42.
Villar J, Belda J, Anon JM, Blanco J, Perez-Mendez L, Ferrando C, et al. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials. 2016;17:342.CrossRefPubMedPubMedCentral
43.
Hite RD, Seeds MC, Jacinto RB, Grier BL, Waite BM, Bass DA. Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis. Biochim Biophys Acta. 2005;1720(1–2):14–21.CrossRefPubMed
44.
Krafft MP. Overcoming inactivation of the lung surfactant by serum proteins: a potential role for fluorocarbons? Soft Matter. 2015;11(30):5982–94.CrossRefPubMed
45.
Seeds MC, Grier BL, Suckling BN, Safta AM, Long DL, Waite BM, et al. Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome. Am J Med Sci. 2012;343(6):446–51.CrossRefPubMedPubMedCentral
46.
Galani V, Tatsaki E, Bai M, Kitsoulis P, Lekka M, Nakos G, et al. The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): an up-to-date cell-specific review. Pathol Res Pract. 2010;206(3):145–50.CrossRefPubMed
47.
Glumoff V, Vayrynen O, Kangas T, Hallman M. Degree of lung maturity determines the direction of the interleukin-1- induced effect on the expression of surfactant proteins. Am J Respir Cell Mol Biol. 2000;22(3):280–8.CrossRefPubMed
48.
Lee JW, Gonzalez RF, Chapin CJ, Busch J, Fineman JR, Gutierrez JA. Nitric oxide decreases surfactant protein gene expression in primary cultures of type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L950–7.CrossRefPubMed
49.
Confalonieri M, Salton F, Fabiano F. Acute respiratory distress syndrome. Eur Respir Rev. 2017;26(144):160116.
50.
Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937–49.CrossRefPubMed
51.
Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18(2):R63.CrossRefPubMedPubMedCentral
52.
Valenza F, Guglielmi M, Maffioletti M, Tedesco C, Maccagni P, Fossali T, et al. Prone position delays the progression of ventilator-induced lung injury in rats: does lung strain distribution play a role? Crit Care Med. 2005;33(2):361–7.CrossRefPubMed
53.
Piedalue F, Albert RK. Prone positioning in acute respiratory distress syndrome. Respir Care Clin N Am. 2003;9(4):495–509.CrossRefPubMed
54.
Kalk P, Senf P, Deja M, Petersen B, Busch T, Bauer C, et al. Inhalation of an endothelin receptor a antagonist attenuates pulmonary inflammation in experimental acute lung injury. Can J Physiol Pharmacol. 2008;86(8):511–5.CrossRefPubMed
55.
Kamiyama J, Jesmin S, Sakuramoto H, Shimojyo N, Islam M, Hagiya K, et al. Hyperinflation deteriorates arterial oxygenation and lung injury in a rabbit model of ARDS with repeated open endotracheal suctioning. BMC Anesthesiol. 2015;15:73.CrossRefPubMedPubMedCentral
56.
Ricci F, Catozzi C, Murgia X, Rosa B, Amidani D, Lorenzini L, et al. Physiological, biochemical, and biophysical characterization of the lung-lavaged spontaneously-breathing rabbit as a model for Respiratory Distress Syndrome. PLoS One. 2017;12(1):e0169190.CrossRefPubMedPubMedCentral
57.
Lutz CJ, Picone A, Gatto LA, Paskanik A, Landas S, Nieman GF. Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury. Crit Care Med. 1998;26(8):1379–89.CrossRefPubMed
58.
Nieman GF, Gatto LA, Paskanik AM, Yang B, Fluck R, Picone A. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med. 1996;24(6):1025–33.CrossRefPubMed
59.
Sun B, Curstedt T, Robertson B. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med. 1996;154(3 Pt 1):764–70.CrossRefPubMed
60.
Zucker AR, Holm BA, Crawford GP, Ridge K, Wood LD, Sznajder JI. PEEP is necessary for exogenous surfactant to reduce pulmonary edema in canine aspiration pneumonitis. J Appl Physiol. 1985;73(2):679–86.CrossRef
61.
Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306(3):L217–30.CrossRefPubMed
62.
Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993;341(8846):643–7.CrossRefPubMed
63.
Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol. 2002;161(5):1783–96.CrossRefPubMedPubMedCentral
64.
Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Phys. 1995;269(1 Pt 1):L109–18 Epub 1995/07/01.
65.
Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Today. 1999;5(6):244–9 Epub 1999/06/15.CrossRefPubMed
66.
De Luca D, Lopez-Rodriguez E, Minucci A, Vendittelli F, Gentile L, Stival E, et al. Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants. Crit Care. 2013;17(4):R163 Epub 2013/07/26.CrossRefPubMedPubMedCentral
67.
Taut FJ, Rippin G, Schenk P, Findlay G, Wurst W, Hafner D, et al. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest. 2008;134(4):724–32.CrossRefPubMed
68.
Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer F. Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation. Biochim Biophys Acta. 2008;1778(10):1947–77.CrossRefPubMed
69.
Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res. 2001;50(1):44–9.CrossRefPubMed
Metadata
Title
Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits
Authors
J. Zebialowicz Ahlström
F. Massaro
P. Mikolka
R. Feinstein
G. Perchiazzi
O. Basabe-Burgos
T. Curstedt
A. Larsson
J. Johansson
A. Rising
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2019
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-019-1220-x

Other articles of this Issue 1/2019

Respiratory Research 1/2019 Go to the issue

Research

Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF

Research

Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression

Review

Isolation and characterization of extracellular vesicles from Broncho-alveolar lavage fluid: a review and comparison of different methods

Research

Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study

Research

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

Research

Salicylic acid amplifies Carbachol-induced bronchoconstriction in human precision-cut lung slices

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits